Quick Answer
Larimar Therapeutics, Inc. reported Cash and Equivalents of $85.41 million for fiscal year 2025.
Larimar Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $85.41M | +157.1% |
| 2024 | $33.22M | +24.2% |
| 2023 | $26.75M | -0.3% |
| 2022 | $26.82M | -61.7% |
| 2021 | $70.10M | +2.9% |
| 2020 | $68.15M | +6654.0% |
| 2019 | $1.01M | -98.0% |
| 2018 | $49.33M | +21.0% |
| 2017 | $40.78M | +26.0% |
| 2016 | $32.35M | -9.1% |
| 2015 | $35.59M | -38.7% |
| 2014 | $58.10M | +63.6% |
| 2013 | $35.52M | +257.5% |
| 2012 | $9.94M | +577.2% |
| 2011 | $1.47M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $90.14M | +157.1% | +337.8% |
| June 30, 2025 | $20.59M | -36.3% | -2.6% |
| March 31, 2025 | $21.13M | -80.8% | -36.4% |
| December 31, 2024 | $33.22M | +24.2% | -5.3% |
| September 30, 2024 | $35.07M | -9.4% | +8.5% |
| June 30, 2024 | $32.31M | -65.7% | -70.7% |
| March 31, 2024 | $110.12M | -1.3% | +311.7% |
| December 31, 2023 | $26.75M | -0.3% | -30.9% |
- Larimar Therapeutics, Inc. showed an increase of +157.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Larimar Therapeutics, Inc.’s cash and equivalents has grown by 5722.2% (from $1.47 million to $85.41 million).
- The most recent figure is from Larimar Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: